Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PODD 194.38 -2.38(-1.21%)
Will PODD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PODD
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Other News for PODD
A Closer Look at 7 Analyst Recommendations For Insulet
Insulet’s Growth Prospects Bolstered by AID Technology and Strategic Market Expansion
Healthcare 2024 Second Half Outlook
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
CereVasc Announces Appointments of New Directors